After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is now planning to merge with New York City-based Neurogene, a… Read More
Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday. The publicly traded Seattle biotech company hired… Read More
Here’s a rundown of the top life sciences and health news across the Pacific Northwest this week. Seagen CEO resigns after domestic violence arrest: Clay Siegall resigned as CEO and… Read More
— The University of Washington announced a new partnership with the National Security Innovation Network (NSIN), a program within the Department of Defense, that will spur students and researchers to… Read More
— Seattle-based ‘alternative VC’ firm Lighter Capital named Melissa Widner as its new CEO. She takes over from former CEO Thor Culverhouse, who replaced longtime Lighter exec BJ Lackland this… Read More
— Seattle-based Vera Whole Health appointed Karen Cooke as chief operating officer. Cooke was most recently vice president of strategic execution and transformation at Sound Physicians. She previously held health-focused… Read More
— Seattle-based Lighter Capital announced Patricia Elliott as chief sales officer and Kevin Fink as chief technology officer. The “alternative VC” company landed a $100 million deal in January to… Read More
Vancouver, B.C.-based Aquinox Pharmaceuticals is set to buy Neoleukin Therapeutics, a Seattle startup that launched out of the University of Washington just eight months ago. Aquinox is paying for the… Read More